ResearcherJinan UniversityActive in the last 2 years

Rongze Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4903-6552; OpenAlex author ID A5083438111. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cance… Co-author DOI 10.1016/j.mtbio.2025.102153 ↗
A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer. Co-author DOI 10.1016/j.actbio.2023.08.007 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yong Wang · 2 shared papers, 2023–2025 · strength 0.48
- Paper A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunothe… DOI 10.1016/j.mtbio.2025.102153 ↗
- Paper A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote th… DOI 10.1016/j.actbio.2023.08.007 ↗
Weiting Jiang · 1 shared paper, 2025 · strength 0.28
- Paper A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunothe… DOI 10.1016/j.mtbio.2025.102153 ↗
Xintao Shuai · 1 shared paper, 2023 · strength 0.19
- Paper A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote th… DOI 10.1016/j.actbio.2023.08.007 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.